207 related articles for article (PubMed ID: 12963346)
1. Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies.
Lee HJ; Im H
Protein Expr Purif; 2003 Sep; 31(1):99-107. PubMed ID: 12963346
[TBL] [Abstract][Full Text] [Related]
2. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli.
Sancho E; Tonge DW; Hockney RC; Booth NA
Eur J Biochem; 1994 Aug; 224(1):125-34. PubMed ID: 8076633
[TBL] [Abstract][Full Text] [Related]
3. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate.
Urano T; Strandberg L; Johansson LB; Ny T
Eur J Biochem; 1992 Nov; 209(3):985-92. PubMed ID: 1425706
[TBL] [Abstract][Full Text] [Related]
4. Expression, purification, and characterization of human enteropeptidase catalytic subunit in Escherichia coli.
Gasparian ME; Ostapchenko VG; Schulga AA; Dolgikh DA; Kirpichnikov MP
Protein Expr Purif; 2003 Sep; 31(1):133-9. PubMed ID: 12963350
[TBL] [Abstract][Full Text] [Related]
5. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Lawrence D; Strandberg L; Grundström T; Ny T
Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
[TBL] [Abstract][Full Text] [Related]
6. Purification and characterization of active and latent forms of recombinant plasminogen activator inhibitor 1 produced in Escherichia coli.
Seetharam R; Dwivedi AM; Duke JL; Hayman AC; Walton HL; Huckins NR; Kamerkar SM; Corman JI; Woodeshick RW; Wilk RR
Biochemistry; 1992 Oct; 31(41):9877-82. PubMed ID: 1382596
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms.
Mikus P; Urano T; Liljeström P; Ny T
Eur J Biochem; 1993 Dec; 218(3):1071-82. PubMed ID: 7506655
[TBL] [Abstract][Full Text] [Related]
8. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
Audenaert AM; Knockaert I; Collen D; Declerck PJ
J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
[TBL] [Abstract][Full Text] [Related]
9. Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type 1 (PAI-1) expressed in Chinese hamster ovary cells: comparison with native human PAI-1.
Strömqvist M; Andersson JO; Boström S; Deinum J; Ehnebom J; Enquist K; Johansson T; Hansson L
Protein Expr Purif; 1994 Aug; 5(4):309-16. PubMed ID: 7950376
[TBL] [Abstract][Full Text] [Related]
10. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
Reilly TM; Mousa SA; Seetharam R; Racanelli AL
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):73-81. PubMed ID: 8180342
[TBL] [Abstract][Full Text] [Related]
11. Kinetically controlled folding of the serpin plasminogen activator inhibitor 1.
Wang Z; Mottonen J; Goldsmith EJ
Biochemistry; 1996 Dec; 35(51):16443-8. PubMed ID: 8987976
[TBL] [Abstract][Full Text] [Related]
12. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).
Alessi MC; Declerck PJ; De Mol M; Nelles L; Collen D
Eur J Biochem; 1988 Aug; 175(3):531-40. PubMed ID: 3261688
[TBL] [Abstract][Full Text] [Related]
13. The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.
Na YR; Im H
Protein Sci; 2005 Jan; 14(1):55-63. PubMed ID: 15576554
[TBL] [Abstract][Full Text] [Related]
14. Polymerization of plasminogen activator inhibitor-1.
Zhou A; Faint R; Charlton P; Dafforn TR; Carrell RW; Lomas DA
J Biol Chem; 2001 Mar; 276(12):9115-22. PubMed ID: 11102455
[TBL] [Abstract][Full Text] [Related]
15. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells.
Liu J; Chen Z; Huang M; Tang S; Wang Q; Hu P; Gupta P; Ashby CR; Chen ZS; Zhang L
Exp Cell Res; 2020 Jun; 391(1):111987. PubMed ID: 32240661
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of recombinant plasminogen activator inhibitor-1 from Escherichia coli.
Reilly TM; Seetharam R; Duke JL; Davis GL; Pierce SK; Walton HL; Kingsley D; Sisk WP
J Biol Chem; 1990 Jun; 265(16):9570-4. PubMed ID: 2188980
[TBL] [Abstract][Full Text] [Related]
18. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
[TBL] [Abstract][Full Text] [Related]
19. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1.
Gils A; Lu J; Aertgeerts K; Knockaert I; Declerck PJ
FEBS Lett; 1997 Sep; 415(2):192-5. PubMed ID: 9350994
[TBL] [Abstract][Full Text] [Related]
20. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
